Form 4 for BBNX Beta Bionics, Inc.
Accepted 2026-09-03 18:15:11 ET · period of report 2026-09-02 · accession 0002048500-26-000012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-03 18:15 | 2026-09-02 | BBNX | Mensinger Mike | Chief Product Off | S - Sale | $19.11 | -4,375 | 180.0K | -2% | -$83.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-02 | S | D | 4,375 | $19.11 | 180,040 | D | — | — | (F1) The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. (F2) The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |